Welcome, and thank you for visiting MetaHeart.

MetaHeart is a medical AI company founded to transform the drug development paradigm by integrating artificial intelligence, digital twin technology, and computational physiology. We develop next-generation digital healthcare technologies that precisely recreate the human heart in a computational environment and use these models to predict the efficacy and safety of pharmaceutical compounds.

Drug development requires substantial time and investment, and promising drug candidates are often discontinued when unexpected cardiac toxicity is identified during clinical trials. To address this challenge, MetaHeart has developed CardioSim®, a platform that combines a physics-based cardiac digital twin with artificial intelligence. By integrating high-fidelity simulations of human cardiac electrophysiology with AI-driven analysis, CardioSim® enables faster and more reliable assessment of drug-induced cardiac safety risks.

In particular, CardioSim® is designed around an assessment framework aligned with the latest CiPA (Comprehensive in Vitro Proarrhythmia Assay) paradigm, supporting cardiac safety evaluations that meet the evolving requirements of the global regulatory environment. This enables pharmaceutical companies and research institutions to predict cardiac toxicity using a more scientific and standardized approach while improving both the efficiency and reliability of the drug development process.

Our goal extends beyond developing software. We aim to create a new research and development environment that enables safer medicines to reach patients more quickly. To achieve this, we collaborate closely with research institutions, pharmaceutical companies, biotechnology companies, and regulatory science experts in Korea and around the world, while continuously advancing our technologies to achieve global standards of performance and reliability.

We believe that technological progress must ultimately serve people. Every research initiative and innovation at MetaHeart is dedicated to developing safer medicines, enabling more precise healthcare, and creating a healthier future.

MetaHeart will continue to develop world-class medical AI technologies and lead innovation across the global biotechnology and healthcare industries.

We sincerely appreciate your continued interest and support.

Thank you.